Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-5,page-paged-5,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea
    www.redhillbio.com
  • Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
    www.adrenomed.com
  • Temedica announces cooperation with Bristol Myers Squibb for the development of a digital companion for psoriasis patients
    www.temedica.com
  • Newron announces 2021 financial results and provides outlook for 2022
    www.newron.com
  • AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
    www.ayoxxa.com
  • Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
    www.abivax.com
  • InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
    www.inflarx.de
  • NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
    www.vaximm.com
  • AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen
    www.aicuris.com
  • RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
    www.redhillbio.com